Results with the fully self-expanding Stanza bioresorbable scaffold in the superficial femoral artery were presented by Andrew Holden, Auckland, New Zealand, at the VEITHsymposium. He also presented initial results with the new, drug-eluting version of the device. In the presentation, Holden, who is director of Interventional Services at Auckland City Hospital and associate professor of Radiology at Auckland University School of Medicine, noted that the advantages of a bioresorbable scaffold for treatment of superficial femoral artery disease include allowing vessel scaffolding while leaving nothing behind, eliminating chronic vessel irritation due to stenting, not having future interventions encumbered by a permanent stent, and also allowing non-invasive imaging with MR angiography.
Hemodyn 2013—The International Vasculab Conference, chaired by Dr Fausto Passariello, was held on 7–9 November 2013 at Accademia Aeronautica di Pozzuoli, Italy.The event was a success with an outstanding attendance and a very interesting scientific programme with important clinical updates on vascular disease. It provided great learning and a huge opportunity for all delegates. The venue was stunning and there was a real buzz of excitement throughout the event.
For the first time, the Charing Cross Symposium announces an open call for two new abstract and poster sessions which will run in parallel to the main programme: the first aimed at all physicians—senior and junior—and the second aimed at vascular scientists, nurses and technologists.
Hypertension is one of the most prevalent diseases in the world and represents a major cardiovascular risk factor. Sympathetic nerves of the renal arteries play an important role in the development of hypertension, and both afferent and efferent nerves are responsible for stimuli that through different mechanisms result in an increase of sympathetic tone.
On 20 December 2013, Endologix announced that it has received investigational device exemption (IDE) approval from the FDA to begin a pivotal clinical trial to evaluate the safety and effectiveness of the Nellix EndoVascular Aneurysm Sealing System (EVAS) for the endovascular repair of infrarenal abdominal aortic aneurysms.
Boehringer Ingelheim has announced results from the RE-COVER II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis and/or pulmonary embolism. In this phase III study, published online in the American Heart Association’s journal Circulation, dabigatran met the primary endpoint of non-inferiority to warfarin for recurrent, symptomatic, objectively-confirmed deep vein thrombosis and/or pulmonary embolism and related deaths during six months of treatment.
Intact Vascular announced on 17 December 2013 the start of enrolment in the TOBA-BTK (Tack optimized balloon angioplasty below the knee) study. This multicentre pilot study will gather data supporting the safety and performance of the Tack-It Endovascular System in patients with critical limb ischaemia due to vascular disease below the knee. A previously enrolled and ongoing clinical trial recruited patients with claudication due to vascular disease for the above-the-knee indication.
Marwan Tabbara, vascular surgeon at the University of Miami Health System, reported using a standard protocol on 855 upper extremity fistulae created over a 10 year period. The findings suggest the use of a standard protocol for creation and management of arteriovenous fistulae can help increase the rate of functional access over the national benchmarks. Additionally, extension/conversions of a malfunctioning fistula to grafts appear to be an excellent method to expedite removal of a tunneled dialysis catheter with concomitant preservation of a fistula.
Gore has announced that the FDA has granted indication for the Gore Viabahn endoprosthesis to treat stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous access grafts.
Simbionix USA Corporation (Cleveland, OH), a provider of medical education and simulation training, announced the release of the Angio Mentor suite, its next-generation simulator platform for endovascular training. The Angio Mentor suite provides clinicians with various platforms on which to practice endovascular skills and full procedures on realistic fluoroscopic images using the same tools used in real procedures. Simbionix introduced the Angio Mentor suite at the VEITH symposium in New York, New York, November 19–22.
Gunnar Tepe (head of Diagnostic and Interventional Radiology, Academic Hospital RoMed, Clinic of Rosenheim, Germany) presented an update on the status of the XXS trial at the VEITHsymposium (19–23 November, New York, USA).
The results from a study looking at interobserver variability in sizing of fenestrated and branched stent grafts have shown a high level of agreement between observer and also some critical discrepancies with may affect clinical results.
Medtronic, Inc. (Minneapolis, MN) announced that the company’s Valiant Mona LSA branch thoracic stent graft system for the treatment of the left subclavian artery (LSA) has demonstrated proof of concept in a first-in-human study. The study, which is being conducted under the US Food and Drug Administration s (FDA) “Innovation Pathway” early feasibility pilot program, enrolled seven patients from the United States. The data were presented at the 2013 VEITH Symposium in New York, New York.
A new study presented at the American Heart Association (AHA) Scientific Sessions in Atlanta and published online in JAMA shows that cell therapy failed to improve walking ability in patients with peripheral arterial disease. Arshed Ali Quyyumi, Emory University School of Medicine, Atlanta, USA, and colleagues studied whether therapy with granulocyte-macrophage colony stimulating factor (GM-CSF), an agent that functions as a white blood cell growth factor, would improve walking performance in patients with symptomatic peripheral artery disease.
Alvimedica Medical Technologies (Catalca, Turkey) announced a merger with CID: Carbostent & Implantable Devices SpA (Saluggia, Italy), which will be joined under the name Alvimedica. The merger provides Alvimedica with three research and development centers in Europe: Catalca, Turkey; Saluggia, Italy; and Assen, the Netherlands. Alvimedica’s global marketing headquarters is in Amsterdam.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos